Sepracor, Inc. Announces Publication Of Additional Data From Lunesta(R) Insomnia-Depression Study In The Journal Of Clinical Sleep Medicine

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that additional data from its Phase IIIB/IV, 545-patient study of LUNESTA® brand eszopiclone in patients with insomnia and co-existing major depressive disorder (MDD) have been published in the February 2007 edition of the Journal of Clinical Sleep Medicine. This manuscript contains results from the two-week, single-blind, placebo run-out period of the study that evaluated hypnotic discontinuation effects following an eight-week, placebo-controlled study of LUNESTA and PROZAC® brand fluoxetine co-therapy in patients with insomnia and co-existing MDD.